2,682
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Roche's recently active trials. Comparator arms are excluded.
- Atezolizumab13 trials
- Inavolisib8 trials
- Giredestrant6 trials
- Bevacizumab6 trials
- Divarasib6 trials
- Pembrolizumab5 trials
Upcoming readouts
Next primary completion dates among Roche's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Nov 2026NAUTIKA1: A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III N…Phase 2
- Jan 2027A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in …Phase 2
- Mar 2027SAkuraSun: A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Sa…Phase 3
- Apr 2027WILL-EMI: A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebra…Phase 3
- Jun 2027FENerations1: A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in…Phase 2
- Jun 2027Study of DONQ52 in Active Celiac DiseasePhase 2
Top therapeutic areas
Conditions studied most often across Roche's recently active trials.
- Breast Cancer5 trials
- Type 2 Diabetes Mellitus4 trials
- Non-small Cell Lung Cancer3 trials
- Obesity or Overweight3 trials
- Diabetic Macular Edema3 trials
- Hemophilia A3 trials
Roche trials
The 50 most significant of Roche's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin AmericaNCT04158258Bevacizumab | — | Not yet scored | OngoingActive, not recruiting | 2,907 est. | 31 Jul 2026 |
| EndomERAA Study of Giredestrant in Participants With Grade 1 Endometrial CancerNCT05634499Giredestrant | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 30 est. | 28 Aug 2026 |
| A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of InavolisibNCT07144111Inavolisib | Phase 1 | Locked · track to reveal | OngoingRecruiting | 32 est. | 4 Sept 2026 |
| A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or ObesityNCT07137585RO7204239 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 30 est. | 14 Sept 2026 |
| A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver FibrosisNCT06903065RO7790121 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 50 est. | 30 Sept 2026 |
| WILL-EMI NISAn Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care TreatmentNCT06883240Von Willebrand Factor Concentrates | — | Not yet scored | OngoingActive, not recruiting | 44 est. | 1 Nov 2026 |
| Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes MellitusNCT06704672Accu-Chek SmartGuide CGM Solution | Na | Locked · track to reveal | OngoingRecruiting | 270 est. | 15 Nov 2026 |
| A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 DiabetesNCT07112872RO7795081 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 240 est. | 27 Nov 2026 |
| NAUTIKA1A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)NCT04302025Alectinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 99 est. | 30 Nov 2026 |
| CieloA Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisNCT05503264Satralizumab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 122 est. | 16 Dec 2026 |
| A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or OverweightNCT07499050RO7795081 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 30 est. | 29 Dec 2026 |
| A Dose-Escalation Study of RO7875913 in Healthy ParticipantsNCT07342114RO7875913 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 40 est. | 31 Dec 2026 |
| WeSMALong-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)NCT05232929Risdiplam | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 403 est. | 31 Dec 2026 |
| A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)NCT03148418Atezolizumab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 382 est. | 31 Dec 2026 |
| A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's LymphomaNCT06806033Obinutuzumab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 100 est. | 31 Jan 2027 |
| SAkuraSunA Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)NCT05199688Satralizumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 8 est. | 31 Mar 2027 |
| A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeNCT07284121Atezolizumab | — | Not yet scored | OngoingRecruiting | 700 est. | 31 Mar 2027 |
| WILL-EMIA Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseNCT06998524Emicizumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 75 est. | 30 Apr 2027 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese ParticipantsNCT07626515Enicepatide | Phase 1 | Not yet scored | OngoingRecruiting | 36 est. | 30 Apr 2027 |
| ReAlecAn Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With AlectinibNCT04764188Alectinib | — | Not yet scored | OngoingActive, not recruiting | 800 est. | 10 May 2027 |
| A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid TumorsNCT06537310RO7567132 and Atezolizumab | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 34 est. | 12 May 2027 |
| FENerations1A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)NCT07161258Fenebrutinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 12 est. | 8 Jun 2027 |
| Study of DONQ52 in Active Celiac DiseaseNCT07239336Simulated Inadvertent Gluten Exposure (SIGE) capsule | Phase 2 | Locked · track to reveal | OngoingRecruiting | 92 est. | 15 Jun 2027 |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate CancerNCT05800665RO7656594 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 210 est. | 30 Jun 2027 |
| ILLUMINATEStudy to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple SclerosisNCT05949580MS Care Platform (icobrain ms and icompanion ms) | — | Not yet scored | OngoingSuspended | 500 est. | 30 Jun 2027 |
| A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)NCT06680817Faricimab | — | Not yet scored | OngoingActive, not recruiting | 850 est. | 30 Jun 2027 |
| PagodaA Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DMENCT04108156PDS Implant Pre-Filled with 100 mg/mL Ranibizumab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 672 est. | 20 Jul 2027 |
| HUTONGA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)NCT05562947PDS With Ranibizumab (100 mg/mL) | Phase 3 | Locked · track to reveal | OngoingRecruiting | 68 est. | 27 Jul 2027 |
| MORPHEUS-LIVERA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)NCT04524871Atezolizumab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 518 est. | 30 Jul 2027 |
| KirrosA Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisNCT06096779Atezolizumab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 30 est. | 30 Jul 2027 |
| A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerNCT07054190Inavolisib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 60 est. | 31 Jul 2027 |
| ZEBRHA 1A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia ANCT07416526NXT007 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 126 est. | 23 Sept 2027 |
| BelvedereA Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)NCT04853251PDS Implant With Ranibizumab 100 mg/ml | Phase 4 | Locked · track to reveal | OngoingRecruiting | 188 est. | 30 Sept 2027 |
| A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)NCT05296798Phesgo | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 922 est. | 31 Oct 2027 |
| IMCODE004A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)NCT06534983Autogene Cevumeran | Phase 2 | Locked · track to reveal | OngoingRecruiting | 62 est. | 10 Nov 2027 |
| ZYNERGYA Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or OverweightNCT07589686Petrelintide | Phase 2 | Locked · track to reveal | OngoingNot yet recruiting | 486 est. | 12 Nov 2027 |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate CancerNCT07567846GDC-1261 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 260 est. | 30 Nov 2027 |
| CENOTEA Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic RetinopathyNCT07588100RO7663498 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 30 est. | 30 Dec 2027 |
| A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart DiseaseNCT07495813RO7763505 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 196 est. | 15 Feb 2028 |
| A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesNCT07670416Enicepatide | Phase 3 | Not yet scored | OngoingRecruiting | 300 est. | 24 Feb 2028 |
| Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)NCT06723106RAY121 | Phase 1 | Locked · track to reveal | OngoingEnrolling by invitation | 144 est. | 28 Feb 2028 |
| ZEBRHA 2A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia ANCT07416604NXT007 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 360 est. | 29 Feb 2028 |
| A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)NCT07531719 | — | Not yet scored | OngoingNot yet recruiting | 30 est. | 1 Mar 2028 |
| HINALEA 2A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene TherapyNCT05861999Risdiplam | Phase 4 | Locked · track to reveal | OngoingRecruiting | 28 est. | 31 Mar 2028 |
| SurfSubQA Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)NCT06780150Ocrelizumab | — | Not yet scored | OngoingRecruiting | 842 est. | 31 Mar 2028 |
| A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaNCT04408638Obinutuzumab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 270 est. | 31 Mar 2028 |
| MintakaA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)NCT07282574RO7268489 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 360 est. | 30 May 2028 |
| Close2HERA Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment DecentralizationNCT07527741 | — | Not yet scored | OngoingRecruiting | 100 est. | 31 May 2028 |
| TRONTIER 2A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseNCT07170150Trontinemab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 800 est. | 7 Jun 2028 |
| Enith1A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045Enicepatide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 2,000 est. | 24 Jul 2028 |